https://brainstorm-cell.com/2026-09-21https://brainstorm-cell.com/news/press-releases/2026-09-21https://brainstorm-cell.com/news/2026/2026-09-21https://brainstorm-cell.com/news/2025/2026-09-21https://brainstorm-cell.com/news/2024/2026-09-21https://brainstorm-cell.com/news/2023/2026-09-21https://brainstorm-cell.com/news/2022/2026-09-21https://brainstorm-cell.com/news/2021/2026-09-21https://brainstorm-cell.com/news/2020/2026-09-21https://brainstorm-cell.com/news/2019/2026-09-21https://brainstorm-cell.com/news/2018/2026-09-21https://brainstorm-cell.com/news/2017/2026-09-21https://brainstorm-cell.com/news/2016/2026-09-21https://brainstorm-cell.com/news/2015/2026-09-21https://brainstorm-cell.com/news/2014/2026-09-21https://brainstorm-cell.com/publications/als/2026-09-21https://brainstorm-cell.com/publications/preclinical/2026-09-21https://brainstorm-cell.com/publications/progressive-ms/2026-09-21https://brainstorm-cell.com/publications/peer-reviewed/2026-09-21https://brainstorm-cell.com/publications/presentations/2026-09-21https://brainstorm-cell.com/science/2026-09-21https://brainstorm-cell.com/science/autologous-cellular-therapy/2026-09-21https://brainstorm-cell.com/science/msc-ntf-cells/2026-09-21https://brainstorm-cell.com/science/cell-production/2026-09-21https://brainstorm-cell.com/science/exosomes/2026-09-21https://brainstorm-cell.com/science/intellectual-property/2026-09-21https://brainstorm-cell.com/pipeline/2026-09-21https://brainstorm-cell.com/pipeline/als/2026-09-21https://brainstorm-cell.com/pipeline/progressive-ms/2026-09-21https://brainstorm-cell.com/publications/2026-09-21https://brainstorm-cell.com/patients/2026-09-21https://brainstorm-cell.com/patients/about-als/2026-09-21https://brainstorm-cell.com/patients/clinical-trials/2026-09-21https://brainstorm-cell.com/patients/expanded-access/2026-09-21https://brainstorm-cell.com/patients/resources/2026-09-21https://brainstorm-cell.com/investors/2026-09-21https://brainstorm-cell.com/news/2026-09-21https://brainstorm-cell.com/about/2026-09-21https://brainstorm-cell.com/about/leadership/2026-09-21https://brainstorm-cell.com/investors/events-and-presentations/2026-09-21https://brainstorm-cell.com/investors/sec-filings/2026-09-21https://brainstorm-cell.com/about/corporate-governance/2026-09-21https://brainstorm-cell.com/careers/2026-09-21https://brainstorm-cell.com/contact/2026-09-21https://brainstorm-cell.com/legal/2026-09-21https://brainstorm-cell.com/accessibility/2026-09-21https://brainstorm-cell.com/sitemap/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-second-quarter-2026-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-former-fda-associate-commissioner-peter-j-pitts-as-executive-chairman/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-publication-calling-for-updated-fda-approaches-to-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-appoints-former-fda-associate-commissioner-peter-j-pitts-to/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-aggregate-of-400-000-in-private-placements-priced/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2026-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-full-year-2025-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-secures-second-1-million-strategic-placement-total-2-million/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-1-million-strategic-financing-at-premium-to-market/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-third-quarter-2025-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-second-quarter-2025-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-nasdaq-delisting-and-transition-to-otcqb/2026-09-21https://brainstorm-cell.com/news/fda-review-of-citizen-petition-offers-a-fresh-look-at-nurown-s/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-new-survival-data-from-expanded-access-program-cohort-remarkably-90/2026-09-21https://brainstorm-cell.com/news/brainstorm-secures-key-manufacturing-partnership-with-minaris-for-upcoming-nurown-phase-3b/2026-09-21https://brainstorm-cell.com/news/brainstorm-receives-fda-clearance-to-initiate-phase-3b-trial-of-nurown-for/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2025-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-reschedules-first-quarter-2025-financial-results-release-to-post-market-close/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-first-quarter-results-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-biomarker-insights-supporting-nurown-s-mechanism-of-action-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-nurown-data-selected-as-breakthrough-science-for-presentation-at-isct/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-submits-ind-amendment-to-fda-paving-the-way-for/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-full-year-2024-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-granted-compliance-extension-from-nasdaq/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2024-financial-results-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2024-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-host-investor-call-and-provide-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-exosome-patent-portfolio-receives-notice-of-allowance-for-u-s/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-host-kol-webinar-on-current-developments-in-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-third-quarter-2024-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-and-pluri-partner-to-support-nurown-phase-3b-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-bid-price-requirement/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-presented-positive-survival-data-from-nurown-expanded-access-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-on-phase-3b-nurown-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-presentations-on-nurown-at-2024-annual-neals-meeting/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-second-quarter-2024-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-second-quarter-results-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-provide-corporate-mid-year-update-on-nurown-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-pricing-of-4-0-million-registered-direct-offering/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reaches-alignment-with-fda-on-cmc-aspects-of-phase/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-appointment-of-haro-hartounian-ph-d-as-chief/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-new-biomarker-data-suggesting-als-patients-may/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2024-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-management-changes-as-company-plans-registrational-phase-3b/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-regains-compliance-with-nasdaq-minimum-market-value-rule/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-biomarker-data-from-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-agreement-with-fda-on-a-special-protocol-assessment/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-provide-update-on-nurown-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-full-year-2023-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-unveil-phase-3b-nurown-trial-design-at-mda/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-submits-special-protocol-assessment-spa-request-to-fda-for/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-european-life-sciences-ceo-forum/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-patents-for-allogeneic-exosome-platform-product-in-neurological-disorder-treatments/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2023-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-outcome-of-fda-meeting-on-nurown-in-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-in-person-meeting-with-the-fda-to-discuss/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-6th-annual-als-research-symposia/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-third-quarter-2023-financial-results-and-provides-corporate/2026-09-22https://brainstorm-cell.com/news/brainstorm-to-announce-third-quarter-2023-financial-results-and-provide-a-corporate/2026-09-22https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-strategic-realignment-prioritizing-nurown-for-the-treatment-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-meet-with-us-fda-to-discuss-development-plan/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-provides-update-on-fda-advisory-committee-meeting-to-review/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-stock-trading-halted-today/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-second-quarter-2023-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-second-quarter-2023-financial-results-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-pricing-of-7-5-million-registered-direct-offering/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-appoints-bob-dagher-m-d-as-executive-vice-president/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-data-show-treatment-with-nurown-significantly-reduces-nfl-a/2026-09-22https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-appoints-nir-naor-as-board-member-and-audit-committee/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-participate-in-the-maxim-group-healthcare-virtual-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-fda-advisory-committee-meeting-to-review-nurown-biologics/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-summarizes-key-messages-from-its-participation-as-expert-speakers/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2023-financial-results-and-provides-corporate/2026-09-22https://brainstorm-cell.com/news/brainstorm-to-announce-first-quarter-2023-financial-results-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-strengthens-leadership-team-with-appointment-of-kirk-taylor-m/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-full-year-2022-financial-results-and-provides-a/2026-09-22https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-fda-advisory-committee-meeting-to-review-biologics-license/2026-09-22https://brainstorm-cell.com/news/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2022-financial-results-and/2026-09-22https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-partners-with-neals-the-als-association-and-i-am/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-biotech-showcase-2023/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-promotion-of-dr-stacy-lindborg-to-co-chief/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-type-a-meeting-with-fda-granted-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-submits-type-a-meeting-request-to-u-s-food/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-third-quarter-2022-financial-results-and-provides-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-receives-refusal-to-file-letter-from-fda-for-its/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-third-quarter-results-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-presents-new-analyses-from-nurown-s-phase-3-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-presents-nurown-phase-2-progressive-ms-biomarker-data-at/2026-09-21https://brainstorm-cell.com/news/brainstorm-presents-new-biomarker-analyses-from-nurown-s-phase-3-als-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-results-from-the-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-second-quarter-2022-financial-results-and-provides-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-second-quarter-results-and-provide-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-presentations-at-june-2022-scientific-conferences/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2022-financial-results-and-provides-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-executive-team-with-key-appointments-in-r-and-d-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-presentation-of-nurown-exosome-preclinical-data-at-isct-2022-san/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-upcoming-scientific-conference-presentations/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-first-quarter-2022-financial-results-and-provide-a-corporate/2026-09-22https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-participate-in-the-2022-virtual-growth-conference-presented/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-full-year-2021-financial-results-and-provides-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-fourth-quarter-and-fiscal-year-2021-financial-results-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-abstract-selected-as-late-breaking-presentation-at-the-2022/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-grant-of-a-new-brazilian-patent-covering-methods/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-12th-annual-california-als-research/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-biotech-showcase-2022/2026-09-21https://brainstorm-cell.com/news/fda-authorizes-further-nurown-dosing-under-expanded-access-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-peer-reviewed-publication-of-nurown-s-phase-3/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-and-catalent-announce-completion-of-technology-transfer-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-new-biomarker-data-on-nurown-at-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-the-presentation-of-new-analyses-from-the-phase/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-third-quarter-2021-financial-results-and-provides-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-expands-leadership-team-to-support-clinical-development-and-medical/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-appointment-of-menghis-bairu-md-to-board-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-third-quarter-financial-results-and-provide-a-corporate-update/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-scientific-presentation-of-nurown-exosome-preclinical-ards-data-at-nyscf/2026-09-21https://brainstorm-cell.com/news/phase-2-clinical-trial-data-of-nurown-in-progressive-ms-will-be/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-als-phase-3-biomarker-analyses-at-annual-neals-meeting/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-the-2021-cell-and-gene-meeting-on-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-phase-2-progressive-ms-study-results-in-oral-presentation/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-second-quarter-2021-financial-results-and-provides-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-increases-commercial-manufacturing-capacity-granted-gmp-certification-for-a-second-production/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-second-quarter-financial-results-and-provide-a-corporate-update-2/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-expansion-of-nurown-ip-portfolio-with-grant-and-allowance-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-scientific-presentation-of-nurown-exosome-preclinical-ards-data-at-isct/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-first-quarter-2021-financial-results-and-provides-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-first-quarter-financial-results-and-provide-a-corporate-update/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-positive-topline-data-in-phase-2-study-evaluating-nurown-as/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-svb-leerink-10th-global-healthcare-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-high-level-fda-feedback-on-nurown-als-clinical-development-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-feedback-from-fda-type-c-meeting-on-future-nurown-manufacturing/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-full-year-2020-financial-results-and-provides-a-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-fourth-quarter-and-fiscal-year-2020-financial/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-the-publication-of-preclinical-data-highlighting-the-potential-of-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2020-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-completion-of-all-dosing-in-nurown-phase-2-ms-study/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-nurown-expanded-access-program/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-nurown-phase-3-clinical-trial-results-at-31st-international/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-topline-results-from-nurown-phase-3-als-study/2026-09-22https://brainstorm-cell.com/news/rapid-reshore-and-development-and-brainstorm-cell-therapeutics-announce-agreement-to-advance/2026-09-21https://brainstorm-cell.com/news/catalent-and-brainstorm-cell-therapeutics-announce-partnership-for-the-manufacture-of-mesenchymal/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-scientific-presentation-of-nurown-exosome-preclinical-ards-outcomes-at-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-third-quarter-of-2020-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-the-2020-cell-and-gene-meeting-on-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-third-quarter-financial-results-and-provide-a/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-scientific-presentation-at-the-annual-neals-meeting/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-william-k-white-as-senior-vice-president-head-of-market/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-grant-of-a-new-japanese-patent-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-scientific-conferences-in-september/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-pharmaceutical-veteran-anthony-waclawski-as-executive-vice-president-global-head/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-data-linking-mri-measures-to-functional-improvement-in-progressive/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-publication-of-new-preclinical-data-supporting-proposed-nurown-mechanism-in/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-the-40th-annual-canaccord-genuity-growth-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-second-quarter-of-2020-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a/2026-09-22https://brainstorm-cell.com/news/brainstorm-announces-groundbreaking-pre-clinical-study-of-nurown-derived-exosome-based-treatment/2026-09-21https://brainstorm-cell.com/news/brainstorm-hosting-kol-webinar-to-discuss-nurown-phase-2-alzheimer-s-disease/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-completion-of-all-dosing-in-nurown-phase-3-clinical-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-showcase-alzheimer-s-disease-clinical-program-in-kol-webinar/2026-09-21https://brainstorm-cell.com/news/brainstorm-expands-clinical-pipeline-to-evaluate-nurown-for-the-treatment-of-alzheimer/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-join-the-russell-2000-index-and-russell-3000/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-sme-status-by-the-european-medicines-agency/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-the-raymond-james-human-health-innovations-conference/2026-09-21https://brainstorm-cell.com/news/the-als-association-i-am-als-award-brainstorm-cell-therapeutics-500-000/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-participate-in-bio-digital-2020/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-that-pivotal-phase-3-trial-remains-on-track-for-topline/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-pharmaceutical-veteran-stacy-r-lindborg-ph-d-as-executive-vice/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-first-quarter-of-2020-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-presents-new-data-highlighting-nurown-immunomodulation-in-neurology/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-first-quarter-financial-results-and-provide-a/2026-09-22https://brainstorm-cell.com/news/brainstorm-awarded-1-5-million-non-dilutive-grant-for-2020-by-the/2026-09-21https://brainstorm-cell.com/news/david-setboun-joins-brainstorm-as-executive-vice-president-and-chief-operating-officer/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-renowned-distinguished-economist-prof-jacob-frenkel-chairman-of-the-board/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-hold-a-conference-call-to-update-investors-on-corporate-steps/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-raises-10-0-million-in-common-stock-sale-at/2026-09-21https://brainstorm-cell.com/news/fifth-and-final-site-announced-for-brainstorm-s-progressive-multiple-sclerosis-phase/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-operational-highlights-and-financial-results-for-the-year-ended-december/2026-09-22https://brainstorm-cell.com/news/brainstorm-s-chief-operating-officer-to-present-at-noble-capital-markets-sixteenth/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-and-fda-agree-to-potential-nurown-regulatory-pathway-for/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-fourth-quarter-and-full-year-2019-financial/2026-09-22https://brainstorm-cell.com/news/brainstorm-ceo-to-provide-company-update-at-the-bio-ceo-and-investor/2026-09-21https://brainstorm-cell.com/news/brainstorm-receives-notice-of-intention-to-grant-additional-eu-patent-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutic-s-coo-and-cmo-dr-ralph-kern-to-present/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-2020-biotech-showcase-and-3rd/2026-09-21https://brainstorm-cell.com/news/nurown-data-safety-monitoring-board-recommends-ms-phase-2-clinical-trial-continue/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2019-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-selected-as-buzz-of-bio-2020-winner/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-make-scientific-presentations-at-the-30th-international-symposium/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-the-mount-sinai-medical-center-as-a-progressive-ms-phase/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-publication-of-nurown-als-phase-2-randomized-clinical/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-third-quarter-of-2019-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-research-grant-award-from-the-national-multiple-sclerosis/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-grant-of-a-new-japanese-patent-for-nurown-2/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-ralph-kern-md-mhsc-to-present-at-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-third-quarter-financial-results-and-provide-a-2/2026-09-22https://brainstorm-cell.com/news/nurown-data-safety-monitoring-board-recommends-als-phase-3-clinical-trial-continue/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-dawson-james-securities-5th-annual/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-president-and-ceo-to-be-featured-as-keynote-speaker/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-presentations-at-neuromuscular-drug-development-summit/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-nurown-phase-3-als-clinical-trial-now-fully-enrolled/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-notice-of-us-patent-allowance-for-nurown-cellular-therapeutic-technology/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-nurown-phase-2-biomarker-data-at-north/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-support-for-fda-guidelines-on-als-drug-development/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-senior-executive-management-team-with-the-appointment-of-preetam-shah/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-late-breaking-news-eposter-at-the-35th/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-second-quarter-of-2019-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-announce-second-quarter-financial-results-and-provide-a-2/2026-09-22https://brainstorm-cell.com/news/third-clinical-site-initiated-for-brainstorm-cell-therapeutic-s-phase-2-progressive/2026-09-21https://brainstorm-cell.com/news/brainstorm-presents-poster-at-consortium-of-multiple-sclerosis-centers-cmsc-33rd-annual/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-second-clinical-site-to-enroll-patients-in-its-progressive-ms/2026-09-21https://brainstorm-cell.com/news/brainstorm-senior-management-to-present-at-bio-2019/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-statement-italian-translation-included/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-world-advanced-therapy-and-regenerative-medicine/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-first-quarter-of-2019-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-cellular-technology-platform-expanded-to-include-exosomes-for-neurodegenerative-diseases/2026-09-21https://brainstorm-cell.com/news/two-brainstorm-scientific-abstracts-accepted-for-presentation-at-the-71st-american-academy/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-grant-of-an-additional-new-european-patent-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-first-patient-enrolled-in-phase-2-clinical-trial-of-progressive/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-business-update-conference-call/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-first-contracted-u-s-clinical-site-for-phase-2-progressive/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-2019-sachs-associates-european-life-sciences-ceo-forum/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-a-statement-to-patients-and-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-2019-bio-ceo-and-investor-conference-and-extracellular/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-2019-noblecon15-annual-investor-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-additional-patent-for-nurown-in-israel/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-nurown-phase-3-study-update-at-the-9th-annual/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-2019-biotech-showcase-and-sachs/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2018-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-expands-manufacturing-of-nurown-for-phase-2-progressive-ms-trial/2026-09-21https://brainstorm-cell.com/news/fda-accepts-brainstorm-s-nurown-ind-application-for-progressive-multiple-sclerosis/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-29th-international-symposium-on-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-submission-of-ind-for-nurown-in-progressive-multiple/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-november-clinical-and-investor-conferences/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-third-quarter-of-2018-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-third-quarter-financial-results-and-provide-corporate-update-on/2026-09-21https://brainstorm-cell.com/news/brainstorm-poster-receives-clinical-abstract-award-at-neals-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-highlights-translational-data-and-presentations-supporting-nurown-technology-platform-as-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-new-u-s-patent-for-industrial-scale-manufacturing-of-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-fda-and-scientific-workshops-highlighting-innovation-in-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-new-presentation-time-at-the-h-c-wainwright/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-arturo-araya-as-chief-commercial-officer/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-at-the-h-c-wainwright/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-successful-interim-safety-analysis-in-phase-3-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-grant-of-a-new-european-patent-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-second-quarter-financial-results-of-2018-and-provide-a/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-japanese-patent-for-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-second-u-s-manufacturing-site-for-nurown-production/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-executive-management-team-with-the-appointment-of-susan-ward-ph/2026-09-21https://brainstorm-cell.com/news/brainstorm-provides-update-on-right-to-try-policy/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-tomorrow-a-conference-call-to-announce-its-right-to/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-exercise-of-warrants-resulting-in-cash-proceeds-of-12-3/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-call-following-president-trump-s-citing-of-company-s/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-provide-corporate-update-at-the-bio-international-convention/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-issues-statement-on-right-to-try-legislation/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-first-quarter-2018-financial-results-and-provides-corporate-and-clinical/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-world-advanced-therapy-and-regenerative-medicine-congress/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-first-quarter-financial-results-and-provide-corporate-update-on/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-participate-in-movement-disorder-panel-at-the-neurotech/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-arm-s-6th-annual-cell-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-phase-3-trial-of-nurown-in-als-now-open/2026-09-21https://brainstorm-cell.com/news/brainstorm-appoints-two-leading-thought-leaders-in-the-fields-of-neuroscience-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-bio-asia-international-conference-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-formation-of-scientific-advisory-board-and-appoints-neuroscientist-jerold-chun/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-operational-highlights-and-financial-results-for-the-year-ended-december-2/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-an-annual-financial-results-call-and-provide-a-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-nurown-phase-2-als-clinical-trial-and-biomarker-abstracts-accepted/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-bio-ceo-and-investor-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-appoints-senior-kite-executive-anthony-polverino-ph-d-to/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-precision-medicine-world-conference-2018-silicon-valley-on/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-gmp-certification-for-a-marketing-level-manufacturing-of-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-issues-2017-letter-to-shareholders/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-10th-annual-biotech-showcase/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-abstracts-on-phase-2-nurown-biomarkers-accepted-for-presentation-at/2026-09-21https://brainstorm-cell.com/news/new-peer-reviewed-publication-shows-that-brainstorm-s-nurown-has-a-unique/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-executive-team-appoints-eyal-rubin-as-chief-financial-officer/2026-09-21https://brainstorm-cell.com/news/brainstorm-expands-its-patent-portfolio-to-include-a-new-us-patent-for/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-third-quarter-2017-financial-results/2026-09-21https://brainstorm-cell.com/news/brainstorm-enrolls-first-patients-in-phase-3-trial-of-nurown-in-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-third-quarter-financial-results-and-provide-corporate-updates-on/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-the-2017-disruptive-growth-company-showcase/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-second-quarter-2017-financial-results/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-second-quarter-2017-financial-results-2/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-second-quarter-2017-earnings-teleconference-and-provide-important-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-supports-commitment-to-als-patient-community-with-appointment-of-a-vice/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-agreement-with-university-of-california-irvine-medical-center-to-participate/2026-09-21https://brainstorm-cell.com/news/brainstorm-awarded-16-million-non-dilutive-grant-from-cirm-in-support-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-agreements-with-mass-general-hospital-and-california-pacific-medical-center/2026-09-21https://brainstorm-cell.com/news/worldwide-clinical-trials-selected-by-brainstorm-as-cro-for-phase-3-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-provide-corporate-update-at-the-bio-international-convention/2026-09-21https://brainstorm-cell.com/news/brainstorm-awarded-2-1-million-non-dilutive-grant-for-2017-by-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-cell-and-gene-exchange-conference-in-washington-dc/2026-09-21https://brainstorm-cell.com/news/brainstorm-initiated-technology-transfer-to-city-of-hope-for-u-s-production/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-first-quarter-2017-financial-results-and-provides-corporate-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-two-scientific-conferences-in-may/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-arm-s-5th-annual-cell-and/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-publication-of-nurown-autism-research-study/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-2016-and-provides-business-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-sachs-associates-2nd-annual-neuroscience-biopartnering/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-management-team-with-appointment-of-ralph-z-kern-md-mhsc/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-mou-with-tel-aviv-sourasky-medical-center-to-make-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-names-dr-june-s-almenoff-and-arturo-o-araya-to-its/2026-09-21https://brainstorm-cell.com/news/brainstorm-seeking-approval-to-distribute-nurown-in-canada/2026-09-21https://brainstorm-cell.com/news/city-of-hope-to-manufacture-nurown-for-brainstorm-s-phase-3-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-bio-ceo-and-investor-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-validation-of-nurown-cryopreservation-process/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-phacilitate-cell-and-gene-therapy-world/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-9th-annual-biotech-showcase/2026-09-21https://brainstorm-cell.com/news/brainstorm-reports-on-successful-end-of-phase-2-meeting-with-fda-upcoming/2026-09-21https://brainstorm-cell.com/news/21st-century-cures-act-passed-by-u-s-congress-provides-an-accelerated/2026-09-21https://brainstorm-cell.com/news/in-depth-analyses-presented-at-international-symposium-on-als-mnd-suggest-strong/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-host-year-end-call-with-investors-to-discuss-important-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-nurown-data-to-be-highlighted-at-the-27th-international-symposium/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reports-third-quarter-2016-financial-results/2026-09-21https://brainstorm-cell.com/news/brainstorm-granted-united-states-patent-for-its-stem-cell-technology/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-two-investor-conferences-in-september/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reports-second-quarter-2016-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-positive-top-line-results-from-the-u-s-phase-2/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-announce-top-line-results-from-the-u-s-phase-2/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-world-stem-cells-and-regenerative-medicine-congress-in/2026-09-21https://brainstorm-cell.com/news/brainstorm-awarded-1-5-million-non-dilutive-grant-for-2016-from-israel/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reports-first-quarter-2016-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-the-israstem-2016-and-the-6th-international-israel/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-2015-and-provides-business-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-to-present-at-bio-asia-international-and-arm-investor-day-conferences/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-nurown-for-the-treatment-of-als-published-in-jama-neurology/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-conduct-phase-2-multi-dose-nurown-trial-in/2026-09-21https://brainstorm-cell.com/news/brainstorm-reschedules-corporate-update-conference-call-to-january-11-2016/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-appointment-of-dr-revital-geffen-aricha-as-vice/2026-09-21https://brainstorm-cell.com/news/brainstorm-hosting-conference-call-to-update-shareholders-on-important-developments/2026-09-21https://brainstorm-cell.com/news/brainstorm-and-octane-biotech-announce-success-in-cocoon-application-development-based-on/2026-09-21https://brainstorm-cell.com/news/brainstorm-awarded-additional-735-000-non-dilutive-grant-for-2015-from-israel/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reports-third-quarter-2015-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-positive-dsmb-review-in-phase-2-trial-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-intellectual-property-position-granted-patent-for-company-s-nurown-technology/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-chief-scientific-advisor-to-present-at-the-2015-fens/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-treatment-of-final-patient-in-us-multicenter-double-blinded-phase/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-2015-stem-cell-meeting-on-the/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-appointment-of-chaim-lebovits-as-chief-executive-officer/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-rodman-and-renshaw-17th-annual-global/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-reports-second-quarter-2015-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-completion-of-enrollment-in-phase-2-clinical-trial/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-report-second-quarter-2015-financial-results-on-thursday/2026-09-21https://brainstorm-cell.com/news/brainstorm-strengthens-executive-team-announces-the-appointment-of-yoram-bibring-as-chief/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-cantor-fitzgerald-s-inaugural-healthcare-conference/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-added-to-russell-microcap-index/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-at-the-bio-international-convention/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-announces-first-quarter-2015-financial-results-and-provides-corporate/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-upcoming-conferences/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-report-first-quarter-2015-financial-results-on-thursday/2026-09-21https://brainstorm-cell.com/news/brainstorm-s-nurown-demonstrates-a-statistically-significant-effect-in-als-patients/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-positive-nurown-phase-2a-clinical-data-at/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-2014-and-provides-business-update/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-report-fourth-quarter-and-full-year-2014-financial/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-present-at-3rd-annual-regen-med-investor-day/2026-09-21https://brainstorm-cell.com/news/brainstorm-receives-notice-of-allowance-for-its-nurown-technology-platform-from-israel/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-the-17th-annual-bio-ceo-and-investor/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-positive-dsmb-recommendation-in-ongoing-phase-2-trial-with-nurown/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-exceptional-preclinical-results-of-nurown-in-mouse-autism-model/2026-09-21https://brainstorm-cell.com/news/brainstorm-enters-into-warrant-exercise-agreement-for-approximately-13-million-in-proceeds/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-receipt-of-approximately-3-1-million-from-warrant-exercises/2026-09-21https://brainstorm-cell.com/news/brainstorm-ceo-to-present-at-two-upcoming-investor-conferences/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-final-analysis-of-phase-2a-als-study-showing-nearly-all/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-host-conference-call-to-discuss-final-results-of/2026-09-21https://brainstorm-cell.com/news/brainstorm-receives-1-100-000-for-its-8th-annual-non-dilutive-grant/2026-09-21https://brainstorm-cell.com/news/brainstorm-announces-financial-results-for-the-third-quarter-of-2014-and-provides/2026-09-21https://brainstorm-cell.com/news/brainstorm-cell-therapeutics-to-report-third-quarter-2014-financial-results-on-thursday/2026-09-21https://brainstorm-cell.com/news/fda-grants-fast-track-designation-to-nurown-for-the-treatment-of-als/2026-09-21https://brainstorm-cell.com/news/brainstorm-reports-last-patient-visit-in-phase-2a-als-study/2026-09-21https://brainstorm-cell.com/news/brainstorm-executive-leadership-to-participate-in-duphat-2026-executive-chairman-peter-j-pitts/2026-09-21https://brainstorm-cell.com/publications/regulatory-fairness-als-rare-disease/2026-09-21https://brainstorm-cell.com/publications/debamestrocel-biomarker-pathways-als/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-cells-progressive-ms/2026-09-21https://brainstorm-cell.com/publications/erratum-phase-3-msc-ntf-als/2026-09-21https://brainstorm-cell.com/publications/phase-3-msc-ntf-als/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-exosomes-acute-lung-injury/2026-09-21https://brainstorm-cell.com/publications/erratum-supplemental-graphs/2026-09-21https://brainstorm-cell.com/publications/csf-biomarkers-phase-3-neals-2021/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-exosomes-ards-model/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-t-and-b-regulatory-cell-function-als/2026-09-21https://brainstorm-cell.com/publications/nurown-phase-2-trial-als/2026-09-21https://brainstorm-cell.com/publications/phase-2-msc-ntf-progressive-ms-cmsc-2019/2026-09-21https://brainstorm-cell.com/publications/vegf-secretion-msc-ntf-cells-als/2026-09-21https://brainstorm-cell.com/publications/csf-caspase-3-phase-2-als/2026-09-21https://brainstorm-cell.com/publications/enrichment-strategies-als-trials/2026-09-21https://brainstorm-cell.com/publications/microrna-changes-phase-2-als/2026-09-21https://brainstorm-cell.com/publications/csf-mirnas-phase-2-als/2026-09-21https://brainstorm-cell.com/publications/alsfrs-r-subscale-domains-phase-2/2026-09-21https://brainstorm-cell.com/publications/mirna-profiling-nurown/2026-09-21https://brainstorm-cell.com/publications/safety-clinical-effects-msc-ntf-als/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-btbr-mouse-model-autism/2026-09-21https://brainstorm-cell.com/publications/concise-review-msc-neurodegenerative-diseases/2026-09-21https://brainstorm-cell.com/publications/safety-repeated-transplantations-msc-ntf/2026-09-21https://brainstorm-cell.com/publications/myasthenia-motor-neuronopathy-case-report/2026-09-21https://brainstorm-cell.com/publications/intrastriatal-msc-ntf-huntingtons-r6-2/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-quinolinic-acid-huntingtons/2026-09-21https://brainstorm-cell.com/publications/differentiated-msc-sciatic-nerve-injury/2026-09-21https://brainstorm-cell.com/publications/intravitreal-msc-ntf-optic-nerve/2026-09-21https://brainstorm-cell.com/publications/icv-msc-ntf-mouse-model-ms/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-6-ohda-parkinson-model/2026-09-21https://brainstorm-cell.com/publications/adult-ntf-secreting-stem-cells/2026-09-21https://brainstorm-cell.com/publications/induction-msc-astrocyte-like-cells-parkinsons/2026-09-21https://brainstorm-cell.com/publications/msc-ntf-migration-mri-quinolinic-acid/2026-09-21https://brainstorm-cell.com/team/peter-pitts/2026-09-21https://brainstorm-cell.com/team/chaim-lebovits/2026-09-21https://brainstorm-cell.com/team/haro-hartounian/2026-09-21https://brainstorm-cell.com/team/uri-yablonka/2026-09-21https://brainstorm-cell.com/team/mary-kay-turner/2026-09-21https://brainstorm-cell.com/team/netta-blondheim-shraga/2026-09-21https://brainstorm-cell.com/team/yossef-levy/2026-09-21https://brainstorm-cell.com/team/alla-patlis/2026-09-21https://brainstorm-cell.com/team/irit-arbel/2026-09-21https://brainstorm-cell.com/team/menghis-bairu/2026-09-21https://brainstorm-cell.com/team/stacy-lindborg/2026-09-21https://brainstorm-cell.com/team/nir-naor/2026-09-21https://brainstorm-cell.com/team/anthony-polverino/2026-09-21https://brainstorm-cell.com/team/jerold-chun/2026-09-21https://brainstorm-cell.com/team/stanley-appel/2026-09-21https://brainstorm-cell.com/team/amit-bar-or/2026-09-21https://brainstorm-cell.com/team/ralph-kern/2026-09-21